Odyssey of a cancer nanoparticle: from injection site to site of action.

No chemotherapeutic drug can be effective until it is delivered to its target site. Nano-sized drug carriers are designed to transport therapeutic or diagnostic materials from the point of administration to the drug's site of action. This task requires the nanoparticle carrying the drug to complete a journey from the injection site to the site of action. The journey begins with the injection of the drug carrier into the bloodstream and continues through stages of circulation, extravasation, accumulation, distribution, endocytosis, endosomal escape, intracellular localization and-finally-action. Effective nanoparticle design should consider all of these stages to maximize drug delivery to the entire tumor and effectiveness of the treatment.

[1]  H. Maeda,et al.  Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[2]  R. Weissleder,et al.  Uptake of dextran‐coated monocrystalline iron oxides in tumor cells and macrophages , 1997, Journal of magnetic resonance imaging : JMRI.

[3]  F. Martin,et al.  Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. , 2004, Seminars in oncology.

[4]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[5]  Justin Hanes,et al.  Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. , 2011, Angewandte Chemie.

[6]  M. Bally,et al.  The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. , 1997, The Journal of pharmacology and experimental therapeutics.

[7]  R. Weiner.  The mechanism of 67Ga localization in malignant disease. , 1996, Nuclear medicine and biology.

[8]  W. Zamboni.  Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents , 2005, Clinical Cancer Research.

[9]  Donald E Ingber,et al.  Can cancer be reversed by engineering the tumor microenvironment? , 2008, Seminars in cancer biology.

[10]  Peter J Houghton,et al.  Establishment of human tumor xenografts in immunodeficient mice , 2007, Nature Protocols.

[11]  Q. Guo,et al.  Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. , 2008, Biomaterials.

[12]  G. Oberdörster,et al.  Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology , 2010, Journal of internal medicine.

[13]  Jayanth Panyam,et al.  Rapid endo‐lysosomal escape of poly(DL‐lactide‐coglycolide) nanoparticles: implications for drug and gene delivery , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[15]  R. Jain,et al.  Solid stress generated by spheroid growth estimated using a linear poroelasticity model. , 2003, Microvascular research.

[16]  Saroja Ramanujan,et al.  Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. , 2002, Biophysical journal.

[17]  Donald E. Henson,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .

[18]  J. B. Hall,et al.  Characterization of nanoparticles for therapeutics. , 2007, Nanomedicine.

[19]  L. Mirny.  Biophysics: Cell commuters avoid delays , 2008 .

[20]  S S Gambhir,et al.  High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R K Jain,et al.  Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. , 1992, Cancer research.

[22]  F. Sharom,et al.  ABC efflux pump-based resistance to chemotherapy drugs. , 2009, Chemical reviews.

[23]  F. Sharom,et al.  Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport. , 1996, The Biochemical journal.

[24]  Robert Langer,et al.  Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. , 2012, ACS nano.

[25]  Ick Chan Kwon,et al.  Tumoral acidic pH-responsive MPEG-poly(beta-amino ester) polymeric micelles for cancer targeting therapy. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[26]  Z. Werb,et al.  Tumors as organs: complex tissues that interface with the entire organism. , 2010, Developmental cell.

[27]  S. Gambhir,et al.  A novel clinically translatable fluorescent nanoparticle for targeted molecular imaging of tumors in living subjects. , 2012, Nano letters.

[28]  R. Jain,et al.  Role of extracellular matrix assembly in interstitial transport in solid tumors. , 2000, Cancer research.

[29]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  K. Bouchemal,et al.  PEGylation and preliminary biocompatibility evaluation of magnetite-silica nanocomposites obtained by high energy ball milling. , 2010, International journal of pharmaceutics.

[31]  K. Braeckmans,et al.  Intracellular partitioning of cell organelles and extraneous nanoparticles during mitosis. , 2012, Advanced drug delivery reviews.

[32]  V. Shahin,et al.  Nuclear envelope barrier leak induced by dexamethasone , 2006, Journal of cellular physiology.

[33]  Faith Davies,et al.  Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. , 2004, Mayo Clinic proceedings.

[34]  R. Vile,et al.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  N. Lassen,et al.  Mechanisms of edema formation in myxedema--increased protein extravasation and relatively slow lymphatic drainage. , 1979, The New England journal of medicine.

[36]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[37]  R. Jain,et al.  A model for temporal heterogeneities of tumor blood flow. , 2003, Microvascular research.

[38]  Ian F Tannock,et al.  The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors , 2010, BMC Cancer.

[39]  C. Davies,et al.  Collagenase Increases the Transcapillary Pressure Gradient and Improves the Uptake and Distribution of Monoclonal Antibodies in Human Osteosarcoma Xenografts , 2004, Cancer Research.

[40]  Esther H Chang,et al.  Does a targeting ligand influence nanoparticle tumor localization or uptake? , 2008, Trends in biotechnology.

[41]  K. Shakesheff,et al.  Polymeric systems for controlled drug release. , 1999, Chemical reviews.

[42]  Robert Langer,et al.  Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.

[43]  A. Berns,et al.  Conditional mouse models of sporadic cancer , 2002, Nature Reviews Cancer.

[44]  J. Israelachvili,et al.  Direct Measurement of a Tethered Ligand-Receptor Interaction Potential , 1997, Science.

[45]  S. Sutton,et al.  Elemental tomography of cancer-cell spheroids reveals incomplete uptake of both platinum(II) and platinum(IV) complexes. , 2007, Journal of the American Chemical Society.

[46]  S. Ammar,et al.  Evaluation of iron oxide nanoparticle biocompatibility , 2011, International journal of nanomedicine.

[47]  G. Fullerton,et al.  Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenografts , 2010, Cancer Chemotherapy and Pharmacology.

[48]  E. Rofstad,et al.  Comparison of tumor blood perfusion assessed by dynamic contrast‐enhanced MRI with tumor blood supply assessed by invasive imaging , 2005, Journal of magnetic resonance imaging : JMRI.

[49]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[50]  R. Shoemaker,et al.  Induction of multiple‐drug resistance during anti‐neoplastic chemotherapy in vitro , 1991, International journal of cancer.

[51]  M. Flessner,et al.  Resistance of Tumor Interstitial Pressure to the Penetration of Intraperitoneally Delivered Antibodies into Metastatic Ovarian Tumors , 2005, Clinical Cancer Research.

[52]  C. Divino,et al.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. , 2009, Cancer research.

[53]  Hua Ai,et al.  Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. , 2006, Nano letters.

[54]  J. Ajani,et al.  Docetaxel-related side effects and their management. , 2009, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[55]  K. Dawson,et al.  Systematic investigation of the thermodynamics of HSA adsorption to N-iso-propylacrylamide/N-tert-butylacrylamide copolymer nanoparticles. Effects of particle size and hydrophobicity. , 2007, Nano letters.

[56]  Indrajit Roy,et al.  In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. , 2010, ACS nano.

[57]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[58]  Zongxi Li,et al.  Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. , 2010, Small.

[59]  Ming-Zher Poh,et al.  Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. , 2010, Biophysical journal.

[60]  M. Garnett,et al.  Nanomedicines and nanotoxicology: some physiological principles. , 2006, Occupational medicine.

[61]  R K Jain,et al.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.

[62]  Gert Storm,et al.  Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system , 1995 .

[63]  J. Wolff,et al.  Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. , 1948, The New England journal of medicine.

[64]  Volker Wagner,et al.  The emerging nanomedicine landscape , 2006, Nature Biotechnology.

[65]  J. Weinstein,et al.  Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. , 1992, Cancer research.

[66]  M. Gottesman.  How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. , 1993, Cancer research.

[67]  C. Liu,et al.  Targeting tumor-associated macrophages as a novel strategy against breast cancer. , 2006, The Journal of clinical investigation.

[68]  Håkan Wallin,et al.  Protracted elimination of gold nanoparticles from mouse liver. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[69]  David A Jaffray,et al.  Cellular uptake and transport of gold nanoparticles incorporated in a liposomal carrier. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[70]  A. Stringaro,et al.  Detection of P-glycoprotein in the Nuclear Envelope of Multidrug Resistant Cells , 2000, The Histochemical Journal.

[71]  R. Langer,et al.  Exploring polyethylenimine‐mediated DNA transfection and the proton sponge hypothesis , 2005, The journal of gene medicine.

[72]  N. Ferrara,et al.  Targeting the tumour vasculature: insights from physiological angiogenesis , 2010, Nature Reviews Cancer.

[73]  S. Davis,et al.  Biomedical applications of nanotechnology--implications for drug targeting and gene therapy. , 1997, Trends in biotechnology.

[74]  R. Jain,et al.  Oncotic pressure in solid tumors is elevated. , 2000, Cancer research.

[75]  C. Pidgeon,et al.  Immobilized-artificial-membrane chromatography: measurements of membrane partition coefficient and predicting drug membrane permeability. , 1996, Journal of chromatography. A.

[76]  Thomas J. Smith,et al.  美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新 , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[77]  Kenneth A. Dawson,et al.  Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.

[78]  D. Fischer,et al.  The Structure of PEG-Modified Poly(Ethylene Imines) Influences Biodistribution and Pharmacokinetics of Their Complexes with NF-κB Decoy in Mice , 2002, Pharmaceutical Research.

[79]  R. K. Jain,et al.  Interstitial fluid pressure in intracranial tumours in patients and in rodents. , 1997, British Journal of Cancer.

[80]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[82]  A. Hasenburg,et al.  Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial) , 2011, BMC Cancer.

[83]  Yasuo Tsutsumi,et al.  Silica nanoparticles as hepatotoxicants. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[84]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[85]  R. B. Campbell,et al.  Role of tumor–host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[86]  C. Allen,et al.  Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[87]  Johnny Yang,et al.  The Characteristics and Mechanisms of Uptake of PLGA Nanoparticles in Rabbit Conjunctival Epithelial Cell Layers , 2004, Pharmaceutical Research.

[88]  T. Allen.  Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.

[89]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[90]  D. Traver,et al.  Characterization of the mononuclear phagocyte system in zebrafish. , 2011, Blood.

[91]  P. Saftig,et al.  At the acidic edge: emerging functions for lysosomal membrane proteins. , 2003, Trends in cell biology.

[92]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[93]  H. Maeda,et al.  Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. , 1992, Bioconjugate chemistry.

[94]  João M.P.Q. Delgado,et al.  A Simple Experimental Technique to Measure Tortuosity in Packed Beds , 2008 .

[95]  H. Jaeger,et al.  Physics of the Granular State , 1992, Science.

[96]  I. Tannock,et al.  Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? , 2012, Cancer cell.

[97]  R. Weinberg,et al.  The Biology of Cancer , 2006 .

[98]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[99]  A. Tall.  Studies on the transfer of phosphatidylcholine from unilamellar vesicles into plasma high density lipoproteins in the rat. , 1980, Journal of lipid research.

[100]  Teruo Okano,et al.  Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymer-Adriamycin conjugates , 1994 .

[101]  Y. Assaraf,et al.  Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[102]  Keely No,et al.  Targeting tumors using estrogen receptor ligand conjugates. , 2009 .

[103]  Y. Maitani,et al.  Collagenase-1 injection improved tumor distribution and gene expression of cationic lipoplex. , 2012, International journal of pharmaceutics.

[104]  E. Fishman,et al.  Tumor transport physiology: implications for imaging and imaging-guided therapy. , 2001, AJR. American journal of roentgenology.